BRPI0611673A2 - modulaÇço sinÉrgica de flt3 cinase empregando-se moduladores de aminopirimidinas cinase - Google Patents

modulaÇço sinÉrgica de flt3 cinase empregando-se moduladores de aminopirimidinas cinase

Info

Publication number
BRPI0611673A2
BRPI0611673A2 BRPI0611673-6A BRPI0611673A BRPI0611673A2 BR PI0611673 A2 BRPI0611673 A2 BR PI0611673A2 BR PI0611673 A BRPI0611673 A BR PI0611673A BR PI0611673 A2 BRPI0611673 A2 BR PI0611673A2
Authority
BR
Brazil
Prior art keywords
kinase
flt3
aminopyrimidine
modulators
modulation
Prior art date
Application number
BRPI0611673-6A
Other languages
English (en)
Inventor
Christian Andrew Baumann
Michael David Gaul
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BRPI0611673A2 publication Critical patent/BRPI0611673A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MODULAÇçO SINÉRGICA DE FLT3 CINASE EMPREGANDO-SE MODULADORES DE AMINOPIRIMIDINAS CINASE. A invenção é direcionada a um método de inibir a atividade ou expressão de FLT3 tirosina cinase ou reduzir a atividade ou expressão de FLT3 cinase em uma célula ou um indivíduo que compreende a administração de um inibidor de farnesil transferase e um inibidor de FLT3 cinase selecionado a partir de compostos de aminopirimidina de Fórmula I': onde R~ 3~, B, Z, r e R1 são como aqui definido. Incluído dentro da presente invenção estão ambos métodos profilácticos e terapêuticos para tratar um indivíduo em risco de (ou suscetível a) desenvolver um distúrbio proliferativo celular ou um distúrbio relacionado a FLT3.
BRPI0611673-6A 2005-06-10 2006-06-07 modulaÇço sinÉrgica de flt3 cinase empregando-se moduladores de aminopirimidinas cinase BRPI0611673A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68971805P 2005-06-10 2005-06-10
PCT/US2006/022391 WO2006135713A2 (en) 2005-06-10 2006-06-07 Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators and a farnesyl transferase inhibitor

Publications (1)

Publication Number Publication Date
BRPI0611673A2 true BRPI0611673A2 (pt) 2009-01-13

Family

ID=37532820

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0611673-6A BRPI0611673A2 (pt) 2005-06-10 2006-06-07 modulaÇço sinÉrgica de flt3 cinase empregando-se moduladores de aminopirimidinas cinase

Country Status (9)

Country Link
US (1) US20060281755A1 (pt)
EP (1) EP1901745A2 (pt)
JP (1) JP2008543771A (pt)
KR (1) KR20080038298A (pt)
CN (1) CN101242837A (pt)
AU (1) AU2006258033A1 (pt)
BR (1) BRPI0611673A2 (pt)
CA (1) CA2611481A1 (pt)
WO (1) WO2006135713A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
MX2008013533A (es) 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.
EP2016070B1 (en) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
PE20211639A1 (es) 2009-01-15 2021-08-24 Incyte Holdings Corp Procesos para preparar inhibidores de jak y compuestos intermediarios relacionado
PT2840080T (pt) 2012-04-17 2018-02-06 Fujifilm Corp Composto heterocíclico que contém azoto ou sal do mesmo
CN104870454B (zh) 2012-08-07 2020-03-03 詹森药业有限公司 用于制备杂环酯衍生物的方法
CN107266405A (zh) 2012-08-07 2017-10-20 詹森药业有限公司 用于制备c‑fms激酶抑制剂的方法
BR112016008080B1 (pt) 2013-10-16 2021-02-23 Fujifilm Corporation sal de ácido carboxílico ou um sal de ácido mineral, cristal de succinato, cristal de fumarato e composição farmacêutica
CN107072995B (zh) 2014-08-22 2020-02-21 富士胶片株式会社 用于处置flt3突变阳性癌的医药组合物、突变型flt3抑制剂以及这些的应用
ES2751623T3 (es) * 2014-10-08 2020-04-01 Inst Nat Sante Rech Med Nuevos compuestos de aminopiridina útiles como inhibidores de la prenilación de proteínas
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
PE20242042A1 (es) 2017-06-02 2024-10-10 Pfizer Anticuerpos especificos para flt3 y sus usos
US12576075B2 (en) 2018-10-30 2026-03-17 Institute For Cancer Research Combination therapies for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117432A (en) * 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EE03484B1 (et) * 1995-12-08 2001-08-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibeerivad (5-imidasolüül)metüül-2-kinolinooni derivaadid ja nende kasutamine
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
BR9916827A (pt) * 1998-12-23 2001-10-16 Janssen Pharmaceutica Nv Derivados de quinolina 1,2-anelados
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US20070021435A1 (en) * 2005-06-10 2007-01-25 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281700A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators

Also Published As

Publication number Publication date
EP1901745A2 (en) 2008-03-26
CA2611481A1 (en) 2006-12-21
AU2006258033A1 (en) 2006-12-21
JP2008543771A (ja) 2008-12-04
WO2006135713A2 (en) 2006-12-21
WO2006135713A3 (en) 2007-08-02
KR20080038298A (ko) 2008-05-06
US20060281755A1 (en) 2006-12-14
CN101242837A (zh) 2008-08-13

Similar Documents

Publication Publication Date Title
BRPI0611923A2 (pt) modulaÇço sinergica da ftl3 quinase usando os moduladores de quinase aminoquinolina e aminoquinazolina
BRPI0611960A2 (pt) modulaÇço sinergÍstica de flt3 cinase empregando tienopirimidina e moduladores de tienopiridina cinase
UA98297C2 (en) Triazolopyridazines as tyrosine kinase modulators
BRPI0611965A2 (pt) modulação sinergìstica de cinase flt3 usando um inibidor de flt3 e um inibidor de farnesil transferase
BRPI0412820A (pt) compostos de aminopirazol e utilização como inibidores de chk1
ECSP077991A (es) Aminopirimidinas como moduladores de cinasa
NO20061194L (no) Mitotiske kinesininbibitorer
BR112014000240A2 (pt) derivados de benzilamina como inibidores de calicreína plasmática
BR0215429A (pt) Composto de fórmula i e seus usos, métodos de inibição da atividade e método de inibição da ativação de um receptor de monoamina, métodos de tratamento, método de identificação de polimorfismo genético e método de identificação de paciente
MX2009002377A (es) Derivados de indazol como moduladores de cinasa asociados con el receptor de interleucina-1.
BRPI0412130A (pt) compostos tetracìclicos como inibidores de c-met
NO20091810L (no) Sammensetninger, set og anvendelser for beskyttelse av huden mot patogene mikroorganismer
MX2010000617A (es) Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
ECSP077994A (es) Aminopirimidinas como moduladores de cinasa
WO2006135713A3 (en) Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators and a farnesyl transferase inhibitor
NO20080162L (no) Tienopyrimidin og tienopyrimidinderivater som FLT-3 kinaseinhibitorer
BRPI0515582A (pt) 3-(2-hidroxifenil)pirazóis e seu uso como moduladores de hsp90
BR112022001054A2 (pt) Inibidores enzimáticos
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
MX2010002042A (es) Derivados de 1,3-dihidroisoindol.
BRPI0514295A (pt) 1, 5-difenilpirazóis
BRPI0518846A2 (pt) composto, composiÇço farmacÊutica, mÉtodos de tratar, ou reduzir o risco de doenÇas ou condiÇÕes em que inibiÇço da enzima mpo É benÉfica e de tratar, ou reduzir o risco de distérbios neuroinflamatàrios, uso de um composto, e, processo para a preparaÇço de um composto
BRPI0612000A2 (pt) modulaÇço sinergÍstica de flt3 cinase usando alquilquinolinas e alquilquinazolinas
BR112023027025A2 (pt) Métodos de uso de inibidores da aldosterona sintase

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: JOHNSON AND JOHNSON (US)

Free format text: TRANSFERIDO DE: JANSSEN PHARMACEUTICA N.V.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]